The United Kingdom’s decision to adopt a mix-and-match vaccination programme ~ one that permits the first shot to be administered using one vaccine and the second with another ~ has drawn widespread criticism. Experts believe that authorities in the UK have been forced to accept this unwieldy compromise because of the shoddy way the vaccination programme was taken up
The Medicines and Healthcare products Regulatory Agency (MHRA) concluded that the vaccine has met its strict standards of safety, quality and effectiveness.
India has bought 1.6 billion doses ~ 500 million doses of the Oxford University-AstraZeneca candidate, one billion from the American company Novavax and 100 million doses of the Sputnik V candidate from Russia’s Gamaleya Research Institute.
